" class="no-js "lang="en-US"> Vincent Charlon - Medtech Alert
Wednesday, March 22, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
Vincent Charlon

Vincent Charlon

About Vincent Charlon

30+ years of experience in global pharmaceutical development
of which 8 years as CEO of a clinical CRO and
15 years as CEO of three successive biotech companies

Related Story

Company Releases

 Tollys and Gustave Roussy Enter into New Research Agreement | Pharmtech Focus

Tollys and Gustave Roussy Enter into New Research Agreement

March 7 2022

Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like […]

Industry News

 Tollys Accelerates Development of TLR3 Agonist Candidates for Intravenous Administration in Immuno-oncology | Pharmtech Focus

Tollys Accelerates Development of TLR3 Agonist Candidates for Intravenous Administration in Immuno-oncology

January 31 2022

Tollys, a biopharmaceutical company developing the first anti-cancer immunotherapy based on a synthetic Toll-Like Receptor […]